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Abstract
Context: Nonfasting (postprandial) triglyceride concentrations have emerged as a clinically significant cardiovascular
disease risk factor that results from accumulation of remnant triglyceride-rich lipoproteins (TRLs) in the circulation.
The remnant TRLs are cleared from the circulation by hepatic uptake, but the specific mechanisms involved are
unclear. The syndecan-1 heparan sulfate proteoglycan (HSPG) pathway is important for the hepatic clearance of
remnant TRLs in mice, but its relevance in humans is unclear.
Objective: We sought to determine whether polymorphisms of the genes responsible for HSPG assembly and
disassembly contribute to atherogenic dyslipoproteinemias in humans.
Patients And Design: We performed an oral fat load in 68 healthy subjects. Lipoproteins (chylomicrons and very low
density lipoproteins 1 and 2) were isolated from blood, and the area under curve and incremental area under curve
for postprandial variables were calculated. Single nucleotide polymorphisms in genes encoding syndecan-1 and
enzymes involved in the synthesis or degradation of HSPG were genotyped in the study subjects.
Results: Our results indicate that the genetic variation rs2281279 in SULF2 associates with postprandial clearance
of remnant TRLs and triglyceride levels in healthy subjects. Furthermore, the SNP rs2281279 in SULF2 associates
with hepatic SULF2 mRNA levels.
Conclusions: In humans, mild but clinically relevant postprandial hyperlipidemia due to reduced hepatic clearance of
remnant TRLs may result from genetic polymorphisms that affect hepatic HSPG.
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Introduction
Nonfasting (postprandial) triglyceride (TG) concentrations
are a clinically significant risk factor for cardiovascular disease
(CVD) [1-3]. TGs are carried in chylomicrons (CMs)
synthesized in the intestine and in liver-derived very low
density lipoprotein (VLDL). Lipolysis of these triglyceride-rich
lipoproteins (TRLs) by lipoprotein lipase (LPL) results in the
formation of smaller remnants particles that are depleted of
triglycerides and enriched in cholesteryl esters [4]. For many
years, CMs and CM remnants were thought to be the major
culprits in postprandial hyperlipidemia [5,6]. However, the
major increase in the postprandial lipoproteins after food intake
occurs in the hepatically derived VLDL remnant particles [7,8].
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A key step in atherogenesis is entrapment of lipoproteins in
the arterial intima [9-11]. Because of their size, most remnant
particles cannot cross the endothelium as efficiently as smaller
low density lipoprotein (LDL) particles [12]. However, since
each remnant particle contain more cholesteryl esters per
particle than do LDL [12], elevated levels of remnants may lead
to accelerated atherosclerosis and CVD.
The mechanism for delayed postprandial hyperlipidemia
involves decreased hepatic clearance of TRL remnants, which
is mediated by the syndecan-1 heparan sulfate proteoglycan
(HSPG) and the LDL receptor [13-18]. The importance of the
HSPG pathway has been questioned, but recent results
demonstrate that dysfunction of syndecan-1 HSPG in animal
models disrupts defective hepatic remnant clearance [13].
Furthermore, in mice with type 2 diabetes, uptake of remnant
lipoproteins is suppressed by accelerated degradation of
HSPG owing to the hepatic induction of a heparan sulfate 6-O-
endosulfatase (SULF2) [19,20].
These findings raise a clinically relevant question: Do
polymorphisms of genes responsible for HSPG assembly and
disassembly contribute to atherogenic dyslipoproteinemias in
humans? To answer this question, we studied healthy subjects
after an oral fat load. Our results indicate association between
a genetic variant of SULF2 and disturbed hepatic clearance of
remnant particles and increased plasma TG in humans.
Patients and Methods
Study design
68 healthy men and women of European descent were
recruited by a newspaper advertisement and from our previous
cohorts of healthy subjects. Inclusion criteria included age 18–
65 years, nonsmoking, and no history of CVD or other severe
disease. The subjects were screened to exclude any
secondary condition affecting lipid levels or abnormalities in
thyroid, liver, or kidney function or in basic blood count. Other
exclusion criteria were use of medications affecting lipid or
glucose metabolism, glycated hemoglobin A1C >6.4%, and
fasting glucose >6.0 mmol/l. The study was approved by the
Ethical Committee of Helsinki University Central Hospital. All
subjects received written (and verbal) information and signed
an informed consent. This form was approved by the ethics
committee. All clinical investigation was conducted according to
the principles expressed in the Declaration of Helsinki.
Oral Fat Load
After a 12-h fast, subjects consumed a mixed meal
consisting of bread, butter, cheese, skim milk, and tea or coffee
(57 g fat, 63 g carbohydrates, and 40 g protein, total 934
calories) in the morning. Blood samples were drawn before and
3, 4, 6, and 8 hours after the meal. During this time, only water
was served ad libitum. The subjects remained physically
inactive throughout the study.
Separation of lipoproteins and biochemical methods
Chylomicrons, VLDL1 and VLDL2 were isolated by gradient
ultracentrifugation [21]. Concentrations of TG, cholesterol,
apolipoprotein (apo) B48, and apoB100 were analyzed in
plasma and in isolated lipoprotein fractions [21]. Plasma
apoB48 was determined with an ELISA (AKHB48, Shibayagi,
Japan). Plasma glucose was measured as described [21], and
plasma insulin was assessed by ELISA (Mercodia, Uppsala,
Sweden). After a heparin bolus of 70 IU/kg, blood samples
were obtained, and LPL and hepatic lipase activities were
determined as described [22].
Determination of liver, subcutaneous, and visceral fat
Liver fat was measured by proton magnetic resonance
spectroscopy and subcutaneous, abdominal, and visceral fat
were measured by magnetic resonance imaging (MRI) [23].
Total abdominal fat was calculated as the sum of visceral and
subcutaneous fat.
Genetic studies
HSPG synthesis is regulated by >35 genes, of which
syndecan-1 (SDC1) and genes associated with initiation,
sulfation or degradation of HSPG have all been associated with
TRL uptake in vitro. In this study we tested if common allelic
variations in SDC1 as well as in genes associated with HSPG
initiation (N-acetylglucosaminyl-proteoglycan-4-beta-
glucuronosyltransferase gene [also called exostosin-1
(EXT1)]), sulfation (heparin sulfate-2-O-sulfotransferase-1
gene: HS2ST1) or degradation (SULF1), were associated with
disturbed hepatic clearance of TRL remnant particles. Single
nucleotide polymorphisms (SNPs) rs2281279 in SULF2,
rs10955854 in EXT1; rs1199668 in HS2ST1; and rs7607854 in
SDC1 were analyzed using Taqman PCR method (Applied
Biosystems, Foster City, CA USA). ABI Prism Sequence
Detection Systems ABI 7900HT was used for post-PCR allelic
discrimination by measuring allele-specific fluorescence.
Genotype distributions did not deviate from Hardy-Weinberg
equilibrium and concordance rate of repeated genotyping was
100%.
Association between rs2281279 genotype and SULF2
expression
SULF2 mRNA expression was assessed in 211 liver biopsies
of subjects of European descent, from the Advanced Study of
Aortic Pathology biobank [24]. Gene expression was measured
by the use of Affymetrix GeneChip Human Exon 1.0 ST arrays
and DNA was genotyped by Illumina Human 610W-Quad
Beadarrays as described [25].
Statistical analysis
Values are presented as median and interquartile range or
as number and proportion. The area under curve (AUC) and
incremental area under curve (IAUC) for postprandial variables
were calculated according to the trapezoid rule. Genotype and
allele frequencies and categorical variables were compared by
Fisher’s exact test or χ2 test. Differences in continuous
variables between the genotypes were assessed by linear
regression analysis after adjustment for age, gender, and body
mass index. Non-normally distributed variables were log-
transformed before entering the model. IBM SPSS Statistics
SULF2 Links to Clearance of TRL Remnants
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e79473
version 20.0 was used for all statistical comparisons (IBM,
Armonk, NY).
Results
Study design
Oral fat load were performed in 68 healthy subjects (Table
1). The age of the study subjects was 47.3 ± 10 years (mean ±
SD), and the distribution between genders male/females was
31/37. There were no significant differences between age and
gender of the genetic variants analyzed (data not shown).
Lipoproteins (chylomicrons, VLDL1, and VLDL2) were isolated
and associations between responses of the postprandial lipids
and common SNPs in genes encoding enzymes involved in the
synthesis or degradation of HSPG were analyzed. Only
rs2281279 in SULF2 was associated with the postprandial
response. The results for EXT1, HS2ST1, and SDC1 are
shown in Tables S1-S3.
Baseline Characteristics of the Study Subjects by the
rs2281279 in SULF2
The frequency of rs2281279 minor G-allele was 0.17 and not
different (P=0.77) from the frequency earlier reported for the
Finnish population (www.1000genomes.org). Carriers of the G
allele had lower fasting plasma TG, lower glucose, and higher
LPL activity (P=0.037, 0.018, and 0.040, respectively; Table
S4) as compared to AA genotype carriers. The rs2281279 did
not associate with liver fat content nor with subcutaneous-,
abdominal-, or visceral fat depots, or other anthropometric/
metabolic variables (Table 1).
Table 1. Baseline Clinical Characteristics of Study
Subjects.
No. of subjects 68
Age (years) 46 (41–53)
Male, n (%) 31 (46)
BMI (kg/m2) 24.1 (22.8–26.1)
Liver fat (%) 1.23 (0.57–3.49)
Total abdominal fat (cm3) 4366 (3315–5778)
Plasma TG (mmol/L) 0.84 (0.67–1.1)
Plasma cholesterol (mmol/L) 4.84 (4.31–5.19)
Plasma HDL-C (mmol/L) 1.58 (1.28–1.82)
Plasma LDL-C (mmol/L) 2.75 (2.46–3.19)
Plasma glucose (mmol/L) 5.40 (5.00–5.60)
Insulin 4.38 (3.24–6.02)
HOMA-IR 0.99 (0.78–1.50)
LPL activity (mU/mL) 174 (125–200)
HL activity (mU/mL) 170 (124–237)
Values are median (interquartile range) or n (%). Fasting triglycerides were
measured at the oral fat load visit. HOMA-IR, homeostasis model assessment for
insulin resistance
doi: 10.1371/journal.pone.0079473.t001
Postprandial triglyceride rich lipoprotein metabolism
After an oral fat load, G allele carriers had a lower AUC for
plasma TG (P=0.016, Figure 1A, Table S5). We next examined
the relative TG content in isolated lipoprotein subclasses. G
allele carriers had a reduced response (AUCs) for TG in the
VLDL1 and VLDL2 fractions (i.e., TG in VLDL1 and VLDL2
particles and in remnant particles of similar densities) (P=0.040
and 0.003, respectively; see Figure 1C, 1D and Table S5). No
differences were observed in the postprandial chylomicron TG
content between the different rs2281279 genotype carriers
(Figure 1B and Table S5).
Next, we measured the amount of intestinal and hepatic
apoB isoforms (apoB48 and apoB100, respectively) in the
lipoprotein subclasses. Carriers of the G allele had statistically
significant reductions in apoB48-containing lipoproteins with
VLDL1 density (i.e., chylomicron remnants within the VLDL1
density range) (Figure 1G, P=0.027) but not in the amount of
apoB48 in VLDL2 (i.e., chylomicron remnants within the VLDL2
density range) or in nonlipolyzed chylomicrons as compared to
AA-genotype carriers. Carriers of the G allele showed a
nonsignificant trend toward lower apoB100 levels in VLDL1 and
VLDL2 than carriers of AA-genotype (Table S5).
LPL activity correlated negatively with both fasting TG (r= –
0.47, P<0.001) and the response (AUC) of postprandial plasma
TG (r= –0.38, P<0.005). LPL also correlated negatively with
AUCs of the TG content of chylomicrons (r= –0.26, P<0.05)
and VLDL1 (r= –0.37, P<0.01).
Association between rs2281279 genotype and SULF2
gene expression
We next analyzed mRNA expression levels in 211 liver
biopsies from the Advanced Study of Aortic Pathology (ASAP)
biobank. Allele and genotype frequencies of rs2281279 were in
Hardy-Weinberg equilibrium (P=0.96 and 1.00, respectively).
The minor allele frequency was 0.21 and not different from that
of our study cohort (P=0.33). G allele of rs2281279 associated
with lower SULF2 mRNA expression in the liver biopsies (AA
(N=131): 7.64±0.34; AG (N=71): 7.58±0.37; GG (N=9):
7.27±0.39, P=0.008).
Discussion
We set up this study to test whether polymorphisms in genes
responsible for HSPG assembly or disassembly associate with
atherogenic dyslipoproteinemias in humans. Our results
suggest that the SNP rs2281279 in SULF2 associates with
postprandial clearance of TRLs and with TG levels in healthy
subjects, and that the reductions in fasting and postprandial TG
levels are due to decreased postprandial TG content in the
VLDL1 and VLDL2 fractions. These lipoprotein fractions contain
chylomicron remnants, VLDL1, or VLDL2 and their VLDL
remnants. Our results further support the finding that the major
increase in postprandial lipoproteins occurs in VLDL remnant
particles [7,8].
The fact that the turnover of chylomicron TG was similar in
the two genotype groups indicates that the lipolysis of TRL
particles is not associated with the SULF2 polymorphism. This
possibility is further supported by the significant negative
SULF2 Links to Clearance of TRL Remnants
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correlations between LPL activity and the postprandial TG
response of both chylomicrons and VLDL1. Consistent with this
finding, carriers of the G allele had a reduced response of
apoB48 in the VLDL1 fraction as compared to AA
homozygotes, suggesting improved clearance of chylomicron
remnant particles. A similar trend towards a reduced apoB100
response in both VLDL1 and VLDL2 was observed in G allele
carriers, consistent with improved clearance of VLDL remnants.
Figure 1.  Postprandial TG and apoB48 in plasma and in lipoprotein subclasses stratified by SULF2 rs2281279
genotype.  Carriers of the G allele had lower AUC for plasma TG (A) and TG content of VLDL1 (C) and VLDL2 (D) than AA
homozygotes; the chylomicron TG content (B) did not differ between the different genotype carriers. Carriers of the G allele had
lower AUC for apoB48 content of chylomicrons (F) and VLDL1 (G) than AA homozygotes; the apoB48 content in plasma (E) and
VLDL2 (H) did not differ between the genotype groups. Data are shown as median (interquartile range). P values were calculated by
linear regression adjusting for age, gender and body mass index (BMI). All the data is specified in Table S5. The number of subjects
is given at the bottom of each column. AA, subjects with two A alleles; AG, heterozygotes; GG, subjects with two G alleles.
doi: 10.1371/journal.pone.0079473.g001
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In healthy subjects, chylomicron remnants and VLDL
remnants compete for clearance [26]. We have further shown
that chylomicrons and VLDL particles are not cleared equally
by LPL and that chylomicrons seem to be the preferred
substrate [27]. Therefore, apoB48-containing remnants should
be cleared preferentially, in line with our findings in this study.
So far, data on the role of SULF2 variants in humans is
limited to an abstract report of subjects with type 2 diabetes, in
whom SULF2 rs2281279 was associated with the levels of both
fasting and postprandial TRLs [28]. We extended that
preliminary observation in an independent population by
showing that SULF2 variation also associates with fasting TG
concentration and postprandial TRL levels in healthy
normolipidemic subjects and that clearance of both
chylomicron remnants and VLDL remnants may be modulated
by SULF2 genotype. Of note, the SNP rs2281279 in SULF2
associates with hepatic SULF2 mRNA levels. This result could
imply that the SULF2 rs2281279 SNP (or a variant in linkage
disequilibrium with it) is involved in regulating SULF2
expression.
The importance of the syndecan-1 HSPG pathway for
hepatic clearance of TRLs in mice has been demonstrated by
systemic deletion of syndecan-1 and hepatocyte-specific
inactivation of sulfotransferases involved in HSPG biosynthesis
[16,29,30]. Furthermore, treatment with SULF2 antisense
oligonucleotides normalizes the defective clearance of TRLs
that results from increased degradation of HSPGs by SULF-2
in animal models of diabetes [13,19,20].
The strengths of this study lie in the design with a thorough
phenotypic characterization combined with oral fat load
analyses. However, we fully acknowledge that a significant
drawback with this study design is that it limits the number of
study subjects and consequently the statistical power to detect
a genetic association. Further weaknesses are that we only
genotyped one SNP per gene despite the fact that each gene
has many common variants for European-descent populations,
and that the multiple testing performed since p-values
(significance) would not survive a conservative correction for
multiple testing. It is therefore important to verify the results
from this study in independent cohorts. Due to the small
sample size, we combined the carriers with the G allele (AG
+GG) when analyzing the associations between responses of
the postprandial lipids and the SNP rs2281279 in SULF2.
However, due to the larger study cohort, we were able to
analyze the genotypes separately when analyzing the
association between rs2281279 genotype and SULF2 gene
expression.
In summary, our results showing that mild, but clinically
relevant, hyperlipidemias in human patients may result from
genetic polymorphisms that affect hepatic HSPG; these
findings indicate that novel targets that improve HSPG-
mediated clearance of remnant particles may be an attractive
strategy to improve metabolic dyslipidemia.
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